Perrigo (NYSE:PRGO) Updates FY25 Earnings Guidance

Perrigo (NYSE:PRGO - Get Free Report) issued an update on its FY25 earnings guidance on Friday morning. The company provided earnings per share guidance of $2.90-3.10 for the period, compared to the consensus earnings per share estimate of $3.01. The company issued revenue guidance of +1-3% yr/yr to $4.42-4.51 billion, compared to the consensus revenue estimate of $4.62 billion. Perrigo also updated its FY 2025 guidance to 2.900-3.100 EPS.

Perrigo Price Performance

Shares of NYSE:PRGO traded up $0.37 during trading hours on Tuesday, hitting $29.37. 3,037,248 shares of the company's stock traded hands, compared to its average volume of 1,490,965. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.77 and a current ratio of 2.56. The company's fifty day simple moving average is $25.00 and its two-hundred day simple moving average is $26.20. Perrigo has a 52 week low of $23.14 and a 52 week high of $33.46. The company has a market cap of $4.01 billion, a price-to-earnings ratio of -25.10 and a beta of 0.54.

Perrigo (NYSE:PRGO - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.01. Perrigo had a positive return on equity of 7.38% and a negative net margin of 3.64%. The company had revenue of $1.14 billion for the quarter, compared to analysts' expectations of $1.20 billion. As a group, equities analysts anticipate that Perrigo will post 2.56 EPS for the current fiscal year.

Remove Ads

Perrigo Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 25th. Stockholders of record on Friday, March 7th will be issued a dividend of $0.29 per share. This represents a $1.16 annualized dividend and a dividend yield of 3.95%. This is an increase from Perrigo's previous quarterly dividend of $0.28. The ex-dividend date of this dividend is Friday, March 7th. Perrigo's dividend payout ratio is currently -92.80%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Piper Sandler downgraded Perrigo from an "overweight" rating to a "neutral" rating and cut their price objective for the stock from $34.00 to $27.00 in a report on Monday, January 6th. StockNews.com lowered shares of Perrigo from a "buy" rating to a "hold" rating in a report on Wednesday, February 19th. Finally, Argus lowered shares of Perrigo from a "buy" rating to a "hold" rating in a research note on Tuesday, January 14th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $33.00.

Insider Activity

In other news, Director Jeffrey B. Kindler sold 17,598 shares of the company's stock in a transaction on Monday, December 9th. The shares were sold at an average price of $28.27, for a total value of $497,495.46. Following the transaction, the director now directly owns 5,409 shares of the company's stock, valued at approximately $152,912.43. This represents a 76.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.70% of the stock is owned by corporate insiders.

Perrigo Company Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.